References
nexium.com
Print this pageEmail this page
For your patients on continuous NSAID therapy


Analysis of pooled data of patients with previous ulcer and/or aged >= 60 years on continuous NSAID therapy

Post-hoc analysis of pooled data from 2 multicenter, randomized, double-blind, placebo-controlled, 6-month studies (n=844 and n=585) comparing NEXIUM 40 mg and NEXIUM 20 mg with placebo administered once daily in at-risk patients (ulcer-free, but aged ≥60 years and/or with a documented history of gastric or duodenal ulcer within the past 5 years) on continuous NSAID therapy.

To what extent can NEXIUM reduce the risk of gastric ulcer?

NEXIUM reduces the risk of gastric ulcer in patients with previous ulcer and/or aged ≥60 years on continuous NSAID therapy

Percent of patients with gastric ulcer with NEXIUM 40 mg, NEXIUM 20 mg, and placebo in individual studies were 5%, 5%, and 17%, respectively (n=795; P<.01), and 3%, 5%, and 12%, respectively (n=569; P<.01).

  • NEXIUM 40 mg QD and NEXIUM 20 mg QD are indicated for the reduction in the occurrence of gastric ulcers associated with continuous NSAID therapy in patients at risk for developing gastric ulcers. Patients are considered to be at risk due to their age (≥60 years) and/or documented history of gastric ulcers. Controlled studies do not extend beyond 6 months.

How would you treat this patient?
View patient profile.



 
Analysis of pooled data from 2 studies of patients aged >= 60 years and/or with a documented history of ulcer on continuous NSAID therapy also taking aspirin

*Aspirin defined as ≤325 mg per day.

Post-hoc analysis of pooled data from 2 multicenter, randomized, double-blind, placebo-controlled, 6-month studies (n=844 and n=585) comparing NEXIUM 40 mg and NEXIUM 20 mg with placebo administered once daily in at-risk patients (ulcer-free, but aged ≥60 years and/or with a documented history of gastric or duodenal ulcer within the past 5 years) on continuous NSAID therapy.

NEXIUM reduces risk of gastric ulcer in patients aged ≥60 years and/or with a documented history of ulcer on continuous NSAID therapy also taking low-dose aspirin

Percent of patients with gastric ulcer with NEXIUM 40 mg, NEXIUM 20 mg, and placebo in individual studies was 5%, 5%, and 17%, respectively (n=795; P<.01), and 3%, 5%, and 12%, respectively (n=569; P<.01).

  • NEXIUM 40 mg QD and NEXIUM 20 mg QD are indicated for reduction in the occurrence of gastric ulcers associated with continuous NSAID therapy in patients at risk for developing gastric ulcers. Patients are considered to be at risk due to their age (≥60 years) and/or documented history of gastric ulcers. Controlled studies do not extend beyond 6 months.

How would you treat this patient?
View patient profile.

Learn how NEXIUM works.
Watch a video presentation.




Important Information

Approved Uses

Pathological Hypersecretory Conditions
NEXIUM is indicated for the long-term treatment of pathological hypersecretory conditions. Dosage regimens should be adjusted to individual patient needs.

Risk Reduction of NSAID-Associated Gastric Ulcer
NEXIUM (esomeprazole magnesium) is indicated for the reduction in the occurrence of gastric ulcers associated with continuous NSAID therapy in patients at risk for developing gastric ulcers. Patients are considered at risk due to their age (≥60 years) and/or documented history of gastric ulcers. Controlled studies do not extend beyond 6 months.

 

Important Safety Information
NEXIUM and NEXIUM I.V. are contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles.

The most frequently reported adverse events with NEXIUM include headache, diarrhea, and abdominal pain. Injection site reactions have also been reported with NEXIUM I.V.

In patients aged 12 to 17 years, the most frequently reported adverse events with NEXIUM include headache, diarrhea, abdominal pain, and nausea.

Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long-term with omeprazole, of which NEXIUM is an enantiomer.

As with all PPIs, patients treated concomitantly with warfarin may need to be monitored for increases in INR and prothrombin time. Like other proton pump inhibitors, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts, and digoxin).

Concomitant administration of esomeprazole may reduce the plasma levels of atazanavir.

NEXIUM should be used only for the conditions, dosages, and durations specified in the Prescribing Information. Please see full Prescribing Information for NEXIUM.

 
 

NEXIUM and the color purple as applied to the capsule are registered trademarks and Purple Plus is a trademark of the AstraZeneca group of companies.
238402 5/07
Copyright © 2007 AstraZeneca LP. All rights reserved.

This product information is intended for US healthcare professionals only.
US Corporate Site





© 2006 AstraZeneca
www.AstraZeneca.com